全文获取类型
收费全文 | 5720篇 |
免费 | 417篇 |
国内免费 | 19篇 |
专业分类
耳鼻咽喉 | 71篇 |
儿科学 | 160篇 |
妇产科学 | 109篇 |
基础医学 | 1024篇 |
口腔科学 | 59篇 |
临床医学 | 624篇 |
内科学 | 1271篇 |
皮肤病学 | 186篇 |
神经病学 | 539篇 |
特种医学 | 202篇 |
外科学 | 784篇 |
综合类 | 42篇 |
一般理论 | 3篇 |
预防医学 | 367篇 |
眼科学 | 102篇 |
药学 | 309篇 |
中国医学 | 6篇 |
肿瘤学 | 298篇 |
出版年
2023年 | 42篇 |
2022年 | 54篇 |
2021年 | 152篇 |
2020年 | 121篇 |
2019年 | 158篇 |
2018年 | 156篇 |
2017年 | 142篇 |
2016年 | 162篇 |
2015年 | 179篇 |
2014年 | 219篇 |
2013年 | 275篇 |
2012年 | 429篇 |
2011年 | 433篇 |
2010年 | 211篇 |
2009年 | 209篇 |
2008年 | 373篇 |
2007年 | 355篇 |
2006年 | 337篇 |
2005年 | 304篇 |
2004年 | 336篇 |
2003年 | 276篇 |
2002年 | 264篇 |
2001年 | 46篇 |
2000年 | 27篇 |
1999年 | 34篇 |
1998年 | 60篇 |
1997年 | 62篇 |
1996年 | 61篇 |
1995年 | 43篇 |
1994年 | 37篇 |
1993年 | 39篇 |
1992年 | 38篇 |
1991年 | 21篇 |
1990年 | 25篇 |
1989年 | 24篇 |
1988年 | 29篇 |
1987年 | 24篇 |
1986年 | 25篇 |
1985年 | 30篇 |
1984年 | 15篇 |
1983年 | 32篇 |
1982年 | 33篇 |
1981年 | 48篇 |
1980年 | 22篇 |
1979年 | 14篇 |
1978年 | 18篇 |
1977年 | 22篇 |
1976年 | 25篇 |
1975年 | 14篇 |
1974年 | 12篇 |
排序方式: 共有6156条查询结果,搜索用时 15 毫秒
91.
The Y-box binding protein YB-1 is associated with progressive disease and mediates survival and drug resistance in multiple myeloma 总被引:1,自引:0,他引:1
下载免费PDF全文
![点击此处可从《Blood》网站下载免费的PDF全文](/ch/ext_images/free.gif)
Chatterjee M Rancso C Stühmer T Eckstein N Andrulis M Gerecke C Lorentz H Royer HD Bargou RC 《Blood》2008,111(7):3714-3722
Current knowledge about molecular mechanisms underlying disease progression and drug resistance in multiple myeloma (MM) is still limited. Here, we analyzed the potential pathogenetic role of the Y-box binding protein YB-1 in MM. YB-1 is a member of the cold-shock domain protein superfamily and involved in various cellular functions such as proliferation. Immunohistochemical analyses revealed that neither normal bone marrow (BM) plasma cells (PCs), premalignant PCs of patients with monoclonal gammopathy of unknown significance (MGUS), nor MM cells with a mature morphology showed expression of YB-1 in situ. In contrast, YB-1 was strongly expressed in situ in normal PC precursor blasts as well as in a MM subset and in vitro in all of the evaluated MM cell lines. The YB-1-expressing MM cells were characterized by an immature morphology and a highly proliferative phenotype as defined by Ki 67 expression. We observed that siRNA-mediated knockdown of YB-1 decreased proliferation and induced apoptosis in MM cells even in the presence of BM stromal cells. Furthermore, we found that overexpression of YB-1 mediated resistance toward doxorubicin-induced apoptosis in MM cells. Thus, YB-1 contributes to disease progression, survival, and drug resistance in MM and might therefore provide an attractive therapeutic target. 相似文献
92.
Gjerdrum LM Woetmann A Odum N Hother C Henrik-Nielsen R Gniadecki R Ralfkiaer E 《European journal of haematology》2008,80(6):483-489
The CD30-positive lymphoproliferations encompass a spectrum of disorders that share histological and phenotypic similarities but differ markedly in clinical behaviour. The basis for this diversity is not known, but it has been proposed that immune suppression by cytokines and/or regulatory T-cells (Tregs) may be implicated. In this study, skin biopsies from lymphomatoid papulosis (LyP) (n = 14), primary cutaneous anaplastic large cells lymphoma (C-ALCL) (n = 13) and systemic anaplastic large cells lymphoma (S-ALCL) with (n = 9) or without (n = 6) ALK expression were examined by immunohistology for FOXP3 expression in tumour cells and tumour infiltrating Tregs. Labelling of a majority of the neoplastic cells was seen in one case of C-ALCL. Another three cases (one LyP and two C-ALCL) displayed weak labelling of very occasional atypical T-cells. In the remaining 38 cases the atypical lymphoid infiltrate was FOXP3 negative. By contrast, all biopsies contained tumour infiltrating FOXP3-positive Tregs. Significant higher numbers were recorded in ALK negative S-ALCL and LyP than in C-ALCL and S-ALCL positive for ALK. In conclusion, it is shown that FOXP3 expression in cutaneous and systemic CD30-positive lymphoproliferations is generally confined to tumour infiltrating Tregs. These cells may have influence upon the clinical behaviour, possibly depending upon the net degree of Treg mediated immune suppression of tumour cells relative to tumour infiltrating, cytotoxic effector cells, thereby implicating the more favourable outcome of LyP compared to C-ALCL. 相似文献
93.
875 Cases of bacterial meningitis: Diagnostic procedures and the impact of preadmission antibiotic therapy Part III of a three-part series 总被引:4,自引:0,他引:4
Vilhelm Bohr Niels Rasmussen Bo Hansen Helge Kjersem Ove Jessen Niels Johnsen Henning S. Kristensen 《The Journal of infection》1983,7(3):193-202
Data on the bacteriological findings, diagnostic measures and clinical course of 875 patients with bacterial meningitis are presented. Findings from the medical records and from a follow-up questionnaire survey of 667 of these cases revealed no significant difference between patients treated with antibiotics before admission (pretreated) and those who were not treated before admission (non-pretreated) with respect to clinical condition on admission, mortality and late sequelae. Pretreatment was, however, associated with a longer duration of symptoms. Apart from cases due to Neisseria meningitidis, there were no significant differences in diagnostic findings between pretreated and non-pretreated cases. In the group of pretreated meningococcal patients, however, positive blood cultures, pleiocytosis in the cerebrospinal fluid (CSF) and positive cultures from sites other than blood and CSF were less frequent than in the non-pretreated cases. 相似文献
94.
Marjolijn Duijvestein Robert Battat Niels Vande Casteele Geert R. D’Haens William J. Sandborn Reena Khanna Vipul Jairath Brian G. Feagan 《Current Treatment Options in Gastroenterology》2018,16(1):129-146
Purpose of review
This article reviews current treatment options and strategies and provides an update on the status of drug development programs of new therapeutic agents for inflammatory bowel diseases (IBD).Recent findings
In the past two decades, tumor necrosis factor antagonist therapy has given clinicians better treatment options. However, not all patients respond to induction therapy with these agents, and of those initially responding, up to 40% ultimately lose response due to suboptimal drug exposure (e.g., caused by immunogenicity), side effects, or other poorly characterized mechanisms. Recently, additional therapies, such as vedolizumab, an integrin blocker that prevents T cell trafficking to the gut, and ustekinumab, an antibody blocking the common p40 subunit of interleukin (IL)-12 and 23, were introduced to the market. In addition, other agents including novel anti-trafficking therapies (e.g., anti-β7 and sphingosine-1-phosphate receptor modulators), antibodies against p19 (unique to IL-23), and small molecules including Janus kinase inhibitors are under investigation in phase II and III trials.Furthermore, the management of IBD has evolved from targeting control of symptoms to suppression of mucosal inflammation. This shift in thinking has been accompanied by the early use of highly effective therapy in poor prognosis patients, accelerated treatment escalation and utilization of a treat to target paradigm approach, and adoption of therapeutic drug monitoring.Summary
The treatment landscape for IBD is rapidly evolving with the recent approval of novel biologics as well as several other agents in late phase of clinical development. Moreover, we have started to use agents more intelligently with a focus on risk stratification and early use of highly effective therapy in high-risk patients, treat to target using patient-reported outcomes (PROs), biomarkers, endoscopy, and therapeutic drug monitoring.95.
Meyerfeldt U Wessel N Schütt H Selbig D Schumann A Voss A Kurths J Ziehmann C Dietz R Schirdewan A 《International journal of cardiology》2002,84(2-3):141-151
BACKGROUND: We tested whether or not heart rate variability (HRV) changes can serve as early signs of ventricular tachycardia (VT) and predict slow and fast VT in patients with an implantable cardioverter defibrillator (ICD). METHODS AND RESULTS: We studied the ICD stored 1000 beat-to-beat intervals before the onset of VT (131 episodes) and during a control time without VT (74 series) in 63 chronic heart failure ICD patients. Standard HRV parameters as well as two nonlinear parameters, namely 'Polvar10' from symbolic dynamics and the finite time growth rates 'Fitgra9' were calculated. Comparing the control and the VT series, no linear HRV parameter showed a significant difference. The nonlinear parameters detected a significant increase in short phases with low variability before the onset of VT (for time series with less than 10% ectopy, P<0.05). Subdividing VT into fast (cycle length 270 ms) events, we found that the onset of slow VT was characterized by a significant increase in heart rate, whereas fast VT was triggered during decreased heart rates, compared to the control series. CONCLUSIONS: Our data may permit the development of automatic ICD algorithms based on nonlinear dynamic HRV parameters to predict VT before it starts. Furthermore, they may facilitate improved prevention strategies. 相似文献
96.
97.
MEK kinase 1 activity is required for definitive erythropoiesis in the mouse fetal liver 总被引:1,自引:0,他引:1
下载免费PDF全文
![点击此处可从《Blood》网站下载免费的PDF全文](/ch/ext_images/free.gif)
Bonnesen B Orskov C Rasmussen S Holst PJ Christensen JP Eriksen KW Qvortrup K Odum N Labuda T 《Blood》2005,106(10):3396-3404
98.
Ole Dyg Pedersen Peter S?ndergaard Tonny Nielsen S?ren Junge Nielsen Eric Steen Nielsen Niels Falstie-Jensen Ingolf Nielsen Lars K?ber Hans Burchardt Marie Seibaek Christian Torp-Pedersen 《European heart journal》2006,27(23):2866-2870
AIMS: Atrial fibrillation (AF) is a risk factor for death in patients with a myocardial infarction, but highly variable results are reported in patients with heart failure. We studied the prognostic impact of AF in heart failure patients with and without ischaemic heart disease. METHODS AND RESULTS: During a period of 2 years, 3587 patients admitted to hospital because of heart failure were included in this study. All patients were examined by echocardiography and the presence of AF was recorded. Follow-up was available for 8 years. Twenty four percent of those discharged alive from hospital had AF. After 4 and 8 years of follow-up, mortality was higher in patients with AF than in patients without, 56 vs. 52% and 77 vs. 73%, respectively. Cox multivariable regression analysis showed a small but significant importance of AF for long-term mortality [hazard ratio (HR) 1.12, 95% confidence limits (CI), 1.02-1.23, P=0.018]. There was a significant interaction between the importance of AF and the presence of ischaemic heart disease (P=0.034). In patients with AF at the time of discharge and ischaemic heart disease, HR was 1.25 (95% CI: 1.09-1.42) and P<0.001; in patients with AF at discharge and without ischaemic heart disease, HR was 1.01 (95% CI: 0.88-1.16) and P=0.88. CONCLUSION: AF is associated with increased risk of death only in patients with ischaemic heart disease. This finding may explain the variable results of studies of the prognosis associated with AF in heart failure. 相似文献
99.
Acute effects of ghrelin administration on glucose and lipid metabolism 总被引:11,自引:0,他引:11
Vestergaard ET Djurhuus CB Gjedsted J Nielsen S Møller N Holst JJ Jørgensen JO Schmitz O 《The Journal of clinical endocrinology and metabolism》2008,93(2):438-444
CONTEXT: Ghrelin infusion increases plasma glucose and nonesterified fatty acids, but it is uncertain whether this is secondary to the concomitant release of GH. OBJECTIVE: Our objective was to study direct effects of ghrelin on substrate metabolism. DESIGN: This was a randomized, single-blind, placebo-controlled two-period crossover study. SETTING: The study was performed in a university clinical research laboratory. PARTICIPANTS: Eight healthy men aged 27.2 +/- 0.9 yr with a body mass index of 23.4 +/- 0.5 kg/m(2) were included in the study. INTERVENTION: Subjects received infusion of ghrelin (5 pmol x kg(-1) x min(-1)) or placebo for 5 h together with a pancreatic clamp (somatostatin 330 microg x h(-1), insulin 0.1 mU x kg(-1) x min(-1), GH 2 ng x kg(-1) x min(-1), and glucagon 0.5 ng.kg(-1) x min(-1)). A hyperinsulinemic (0.6 mU x kg(-1) x min(-1)) euglycemic clamp was performed during the final 2 h of each infusion. RESULTS: Basal and insulin-stimulated glucose disposal decreased with ghrelin [basal: 1.9 +/- 0.1 (ghrelin) vs. 2.3 +/- 0.1 mg x kg(-1) x min(-1), P = 0.03; clamp: 3.9 +/- 0.6 (ghrelin) vs. 6.1 +/- 0.5 mg x kg(-1) x min(-1), P = 0.02], whereas endogenous glucose production was similar. Glucose infusion rate during the clamp was reduced by ghrelin [4.0 +/- 0.7 (ghrelin) vs. 6.9 +/- 0.9 mg.kg(-1) x min(-1); P = 0.007], whereas nonesterified fatty acid flux increased [131 +/- 26 (ghrelin) vs. 69 +/- 5 micromol/min; P = 0.048] in the basal period. Regional lipolysis (skeletal muscle, sc fat) increased insignificantly with ghrelin infusion. Energy expenditure during the clamp decreased after ghrelin infusion [1539 +/- 28 (ghrelin) vs. 1608 +/- 32 kcal/24 h; P = 0.048], but the respiratory quotient did not differ. Minor but significant elevations in serum levels of GH and cortisol were observed after ghrelin infusion. CONCLUSIONS: Administration of exogenous ghrelin causes insulin resistance in muscle and stimulates lipolysis; these effects are likely to be direct, although a small contribution of GH and cortisol cannot be excluded. 相似文献
100.